Medicare Plan Comparison Strategies to Increase Patient Retention and Grow Revenue LEARN MORE

EnlivenHealth Launches Patient Engagement Network (PEN) Designed to Help Pharmaceutical Manufacturers and Retail Pharmacies Improve Patient Health Outcomes, Drive Revenue Growth

Leveraging EnlivenHealth’s Robust National Pharmacy Network, PEN is Intended to Enable Pharma and Consumer Health Brands to Deliver Automated, Branded, Omnichannel Patient Messaging

FORT WORTH, TX – December 2, 2022 – EnlivenHealth®, the retail pharmacy solutions division of Omnicell, Inc. (Nasdaq: OMCL), today announced the launch of the Patient Engagement Network (PEN), a comprehensive patient engagement solution that combines EnlivenHealth’s broad national pharmacy network with best-in-class data insights and digital engagement technologies that is designed to help improve patient health outcomes, improve brand loyalty and drive revenue growth.

EnlivenHealth’s new PEN solution connects targeted patients with branded educational messaging ‒ all optimized to be delivered when, where and how individual patients prefer to receive their health-related information. For participating pharmacies, PEN should offer a new revenue growth channel by partnering with leading pharmaceutical manufacturers and consumer health brands.

In today’s changing, post-COVID-19 pandemic environment, patients continue to assume a greater role in their healthcare decisions as they seek trusted medical information outside of their prescriber’s office. For life sciences companies and health-related consumer packaged goods brands, we find the challenge is delivering the right messaging to patients, at the right time, and in the right place. We believe that to be effective, every patient interaction needs to be relevant and engaging, as well as conveniently delivered.

With the launch of PEN, EnlivenHealth is making its patient engagement technology solutions available to pharma and life sciences companies for the intended purpose to help achieve this critical patient health mission. PEN is designed to achieve this through automated, direct-to-consumer messaging campaigns that are provided free of charge to participating retail pharmacies. EnlivenHealth is currently collaborating with leading pharmaceutical manufacturers and life sciences companies in their development of innovative patient engagement campaigns.

“PEN capitalizes on EnlivenHealth’s unique assets and capabilities, including our extensive national pharmacy network that reaches patients in virtually every community nationwide, and our industry-leading digital engagement technologies,” said Danny Sanchez, senior vice president and general manager of EnlivenHealth. “What we think differentiates PEN is that it is intended to combine the power of digital engagement with the high level of trust that patients have in their local pharmacies and pharmacists. We believe PEN fills a significant need in the marketplace for both branded and above brand patient engagement, which in our view represents a win-win for everyone: pharmacies, manufacturers, and most important, patients.”

EnlivenHealth’s new PEN solution is meant to provide partners with the following important benefits:

  • Ability to target patients by condition, age, geography, medication adherence and payer
  • Automated, outbound notifications through voice, SMS text, mobile push, email, mail
  • Intelligent, interactive personalized IVR (Interactive Voice Response)
  • Mobile and web applications
  • Interactive web forms
  • Pharmacy appointment scheduling

To learn more about EnlivenHealth’s Patient Engagement Network solution or to schedule a demo, visit enlivenhealth.co.


About EnlivenHealth®

EnlivenHealth® builds advanced patient engagement, financial management and population health technology solutions that enable retail pharmacies and health plans to measurably improve the health of their patients and members, while ensuring the long-term health of their business. With the recent acquisitions of FDS Amplicare and MarkeTouch Media, EnlivenHealth® now offers the industry’s most comprehensive suite of SaaS technology solutions that help retail pharmacies and health plans to transform and thrive in this new era of digital-driven healthcare. Currently, more than 50,000 retail pharmacies nationwide deploy EnlivenHealth®/FDS Amplicare/MarkeTouch Media technology solutions. EnlivenHealth® is a division of Omnicell, Inc. (Nasdaq: OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies. To learn more, visit EnlivenHealth.co.

ENLIVENHEALTH is a registered trademark of Omnicell, Inc. or one of its subsidiaries.

About Omnicell

Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and technology-enabled services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings. Healthcare facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. Institutional and retail pharmacies across North America and the United Kingdom leverage Omnicell’s innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions. To learn more, visit www.omnicell.com.

Forward-Looking Statements

Certain statements contained in this press release relate to the expected benefits and objectives of EnlivenHealth’s products and services, including EnlivenHealth’s Patient Engagement Network solution (and any implied financial impact in connection with the foregoing). These statements are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties some of which are beyond our control. These risks and uncertainties include, among other things, (i) risks related to the ongoing COVID-19 pandemic (including new variants of the virus), (ii) Omnicell’s ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions, (iii) continued and increased competition from current and future competitors in the medication management automation solutions market and the medication adherence solutions market, (iv) unfavorable general economic and market conditions or reduction in demand for our solutions, (v) risks related to Omnicell’s investments in new business strategies or initiatives, including its transition to selling more products and services on a subscription basis, (vi) any disruption in Omnicell’s information technology systems and breaches of data security or cyber-attacks on its systems or solutions, including the previously disclosed ransomware incident and any potential adverse legal, reputational and financial effects that may result from it and/or additional cybersecurity incidents, as well as the effectiveness of business continuity plans during any future cybersecurity incidents, (vii) Omnicell’s ability to meet the demands of, or maintain relationships with, its institutional, retail, and specialty pharmacy customers, and (viii) other risks and uncertainties further described in the “Risk Factors” section of Omnicell’s most recent Annual Report on Form 10-K, as well as in Omnicell’s other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at www.sec.gov. Forward-looking statements should be considered in light of these risks and uncertainties. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law.

Contact:

Eric T. Reese, EnlivenHealth®
919-423-4510
eric.reese@omnicell.com